Evidence map›Paper›PMID 33246296›Full record

ReviewRespiratory medicine2021

Smoking and COVID-19: What we know so far.

Madhur D Shastri, Shakti D Shukla, Wai Chin Chong, Rajendra Kc, Kamal Dua, Rahul P Patel, Gregory M Peterson, Ronan F O'Toole

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Madhur D ShastriSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, Australia. Electronic address: Madhur.Shastri@utas.edu.au.
Shakti D ShuklaPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute and the University of Newcastle, Callaghan, Australia.
Wai Chin ChongDepartment of Molecular and Translational Science, Monash University, Clayton, Australia.
Rajendra KcTasmanian School of Medicine, College of Health and Medicine, University of Tasmania, Tasmania, Australia.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo NSW, Australia.
Rahul P PatelSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, Australia.
Gregory M PetersonSchool of Pharmacy and Pharmacology, University of Tasmania, Hobart, Australia.
Ronan F O'TooleDepartment of Pharmacy and Biomedical Sciences, School of Molecular Sciences, College of Science, Health and Engineering, La Trobe University, La Trobe, Australia. Electronic address: r.otoole@latrobe.edu.au.
University of Tasmania · AUHunter Medical Research Institute · AULa Trobe University · AUMonash University · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing COVID-19 pandemic has placed a spotlight on infectious diseases and their associations with host factors and underlying conditions. New data on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus are entering the public domain at a rapid rate such that their distillation often lags behind. To minimise weak associations becoming perceived as established paradigms, it is imperative that methodologies and outputs from different studies are appropriately critiqued and compared. In this review, we examine recent data on a potential relationship between smoking and COVID-19. While the causal role of smoking has been firmly demonstrated in regard to lung cancer and chronic obstructive pulmonary disease, such associations have the benefit of decades' worth of multi-centre epidemiological and mechanistic data. From our analysis of the available studies to date, it appears that a relationship is emerging in regard to patients with a smoking history having a higher likelihood of developing more severe symptoms of COVID-19 disease than non-smokers. Data on whether COVID-19 has a greater incidence in smokers than non-smokers is thus far, contradictory and inconclusive. There is therefore a need for some caution to be exercised until further research has been conducted in a wider range of geographical settings with sufficient numbers of patients that have been carefully phenotyped in respect of smoking status and adequate statistical control for confounding factors.

Indexed as

COVID-19HumansRisk FactorsSmokingAngiotensin-converting-enzyme (ACE)-IICoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SmokingTherapeutic targets

Identifiers

PMID33246296
PMCPMC7674982
OpenAlexW3105487129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.